23andMe Holding Co.
Change company Symbol lookup
Select an option...
ME 23andMe Holding Co.
RKDA Arcadia Biosciences Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
GIC Global Industrial Co
EQHA EQ Health Acquisition Corp
DLCAW Deep Lake Capital Acquisition Equity Warrant Exp 04 Jan 2026 *W EXP 01/04/2026
CDK CDK Global Inc
CNC Centene Corp
ONXXF Ontex Group NV
INDB Independent Bank Corp (Massachusetts)
Go

Company profile

23andMe Holding Co., formerly VG Acquisition Corp., is a consumer genetics and research company. The Company offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The Company operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

Closing Price
$2.88
Day's Change
-0.04 (-1.37%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.01
Day's Low
2.74
Volume
(Light)
Volume:
2,476,752

10-day average volume:
3,140,129
2,476,752

Company Profile

23andMe Holding Co., formerly VG Acquisition Corp., is a consumer genetics and research company. The Company offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The Company operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
5.04x
Price/Book (MRQ)
1.36x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

April 2022
Current Month
30.5M
Previous Month
28.7M
Percent of Float
15.23%
Days to Cover
12.3405 Days

Share Information

ME is in a share class of common stock
Float
334.5M
Shares Outstanding
447.1M
Institutions Holding Shares
162
30.11%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

During the most recent quarter, 11K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.